Xencor, Inc. develops engineered antibody therapeutics for cancer and autoimmune diseases using its XmAb technology platform and related antibody-engineering formats. News about XNCR commonly covers clinical and preclinical updates for XmAb drug candidates, including TL1A programs such as XmAb942 and XmAb412, T-cell engaging bispecific antibodies such as XmAb819 and XmAb541, and presentations of data at medical meetings.
Recurring company updates also include quarterly financial results, research-and-development priorities, collaboration and licensing activity, intellectual-property developments tied to Xtend Fc domain technology, and royalty matters involving partner-marketed medicines such as Ultomiris.
Xencor, Inc. (NASDAQ: XNCR) will announce its second quarter 2022 financial results post-market on August 3, 2022. A conference call and webcast will take place at 4:30 p.m. ET to discuss these results alongside a corporate update. The webcast will be accessible on the company's investor website and available for archiving for 30 days.
Xencor specializes in developing engineered antibodies and cytokines aimed at treating cancer and autoimmune disorders, with over 20 candidates in clinical development using its advanced XmAb® technology.
Xencor, Inc. (NASDAQ:XNCR) recently announced initial data from the Phase 1 clinical study of XmAb104, a bispecific antibody targeting PD-1 and ICOS, in patients with advanced solid tumors. Results will be presented at the ASCO Annual Meeting on June 5, 2022. The study aims to assess safety and tolerability while determining the maximum tolerated dose (MTD). With 62 patients treated, XmAb104 showed a distinct safety profile, and two confirmed partial responses were observed. The recommended dose for further study is 10 mg/kg, suggesting promising therapeutic potential.
Xencor, a clinical-stage biopharmaceutical company, reported strong Q1 2022 results, highlighting revenues of $85.5 million, up from $34 million in Q1 2021. The company has a robust financial position with $683.6 million in cash and marketable securities. Key developments include dosing the first patient in a Phase 2 trial for plamotamab. However, Xencor foresees a decline in future royalty revenues from sotrovimab. Overall, the company is advancing multiple clinical programs while maintaining a net income of $23.6 million or $0.39 per diluted share.
Xencor, Inc. (NASDAQ: XNCR), a biopharmaceutical company focused on engineered antibodies and cytokines, will release its first quarter 2022 financial results on May 5, 2022, after market close. A conference call and webcast will be held that same day at 4:30 p.m. ET to discuss the results and provide corporate updates. The event can be accessed via phone or through the company’s website. Currently, more than 20 candidates utilizing Xencor’s XmAb® technology are in clinical development, with three marketed by partners.
Xencor, Inc. (NASDAQ: XNCR) has presented new data on its preclinical-stage IL-18 and LAG3-targeted IL-15 cytokine programs at the AACR Annual Meeting 2022. The company introduced a decoy-resistant IL18-Fc fusion protein and a LAG-3 targeted IL15/IL15Rα-Fc fusion protein aimed at preferential TIL expansion. Xencor plans to submit an investigational new drug application for XmAb662 later this year, a promising IL12-Fc cytokine with observed anti-tumor activity. These developments aim to enhance cytokine therapeutics' efficacy while reducing systemic toxicity.
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company, announced it will present preclinical data on two new XmAb® cytokine programs at the AACR Annual Meeting in New Orleans from April 8-13, 2022. The data includes a decoy-resistant IL18-Fc fusion protein and a LAG-3 targeted IL15/IL15α-Fc fusion protein. The presentations are scheduled for April 11 and April 12, highlighting their innovative approaches to enhance immune responses in cancer treatment. Xencor's XmAb technology enables the creation of long-acting therapeutic candidates for improved patient outcomes.
Xencor, a clinical-stage biopharmaceutical company, reported its financial results for Q4 and FY 2021, highlighting significant advancements in its drug portfolio. The company initiated Phase 2 trials for vudalimab in prostate cancer and established a collaboration with Janssen. Revenues surged to $154 million in Q4, compared to $42 million in Q4 2020, while full-year revenues reached $275 million, up from $123 million. Net income for 2021 was $82.6 million, a turnaround from a net loss of $69.3 million in 2020. Xencor expects to maintain cash reserves of $500-$550 million by the end of 2022.
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company, announced it will provide a corporate update and report financial results for Q4 and full year 2021 after market close on February 23, 2022. Management will host a conference call at 4:30 p.m. ET to discuss the updates. Xencor is developing engineered monoclonal antibodies and cytokines to treat cancer and autoimmune diseases, with 22 candidates currently in clinical development.
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company focused on engineered monoclonal antibodies and cytokines for cancer and autoimmune diseases, will participate in two virtual investor conferences. The first is the Guggenheim Healthcare Talks | 2022 Oncology Conference on February 9, 2022, at 2:00 p.m. EST. The second is the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 3:40 p.m. EST. Live webcasts will be accessible on Xencor's website, with replays available for 30 days.
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company, announced its corporate priorities for 2022, focusing on advancing bispecific antibody and engineered cytokine programs for cancer and autoimmune diseases. Key projects include vudalimab and plamotamab, with planned Phase 2 studies in various cancers. Xencor reported a cash position of approximately $660 million, sufficient to fund operations through 2025. The company anticipates new clinical data that may enhance its portfolio, which includes 22 candidates in development, leveraging its XmAb technology.